BusinessGalectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017By Nasdaq OMXApr 18, 2017, 12:01 PM UTC
BusinessGalectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017By Nasdaq OMXApr 18, 2017, 12:01 PM UTC
BusinessOcera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)By Nasdaq OMXApr 12, 2017, 8:08 PM UTC
BusinessOcera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)By Nasdaq OMXApr 12, 2017, 8:08 PM UTC
BusinessOcera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)By Nasdaq OMXApr 12, 2017, 8:08 PM UTC
BusinessOcera to Present at the 16th Annual Needham Healthcare ConferenceBy Nasdaq OMXMar 27, 2017, 8:05 PM UTC
BusinessGalectin Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business UpdateBy Nasdaq OMXMar 21, 2017, 12:30 PM UTC
BusinessOcera Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate UpdateBy Nasdaq OMXMar 10, 2017, 11:00 AM UTC
